Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
9.39
Dollar change
-1.15
Percentage change
-10.91
%
IndexRUT P/E- EPS (ttm)-2.73 Insider Own44.95% Shs Outstand22.52M Perf Week-6.01%
Market Cap289.87M Forward P/E- EPS next Y-3.20 Insider Trans20.42% Shs Float17.00M Perf Month49.28%
Income-60.39M PEG- EPS next Q-0.89 Inst Own62.06% Short Float3.14% Perf Quarter115.86%
Sales0.00M P/S- EPS this Y-17.34% Inst Trans- Short Ratio0.74 Perf Half Y71.98%
Book/sh5.38 P/B1.75 EPS next Y0.48% ROA-37.80% Short Interest0.53M Perf Year-9.19%
Cash/sh4.13 P/C2.27 EPS next 5Y- ROE-41.41% 52W Range3.19 - 14.30 Perf YTD90.85%
Dividend Est.- P/FCF- EPS past 5Y- ROI-48.33% 52W High-34.34% Beta0.80
Dividend TTM- Quick Ratio9.75 Sales past 5Y0.00% Gross Margin- 52W Low194.36% ATR (14)1.19
Dividend Ex-Date- Current Ratio9.75 EPS Y/Y TTM-83.06% Oper. Margin0.00% RSI (14)60.25 Volatility13.87% 13.62%
Employees58 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.44
Option/ShortNo / Yes LT Debt/Eq0.03 EPS Q/Q-101.64% Payout- Rel Volume0.87 Prev Close10.54
Sales Surprise- EPS Surprise-18.13% Sales Q/Q- EarningsMar 28 BMO Avg Volume723.72K Price9.39
SMA2019.13% SMA5058.93% SMA20029.55% Trades Volume627,504 Change-10.91%
Date Action Analyst Rating Change Price Target Change
Mar-01-24Initiated JMP Securities Mkt Outperform $14
Dec-15-23Resumed Jefferies Buy $17 → $12
Oct-05-23Initiated Maxim Group Buy
Jun-02-23Initiated Oppenheimer Outperform $25
May-08-23Initiated BMO Capital Markets Outperform $25
Apr-27-23Initiated Ladenburg Thalmann Buy $22
Apr-20-23Initiated H.C. Wainwright Buy $24
Dec-12-22Initiated Piper Sandler Overweight $25
Dec-12-22Initiated Jefferies Buy $17
Dec-12-22Initiated Cowen Outperform
Apr-16-24 08:01PM
Apr-10-24 08:00AM
Apr-09-24 10:32AM
07:00AM
Mar-30-24 05:31AM
12:52PM Loading…
Mar-28-24 12:52PM
08:00AM
Mar-05-24 04:30PM
Mar-04-24 08:00AM
Feb-27-24 08:00AM
Feb-08-24 08:00AM
Feb-06-24 08:00AM
Jan-12-24 04:00PM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
08:00AM Loading…
Nov-28-23 08:00AM
Nov-21-23 08:00AM
08:00AM
Nov-09-23 08:01AM
Oct-16-23 08:00AM
Sep-28-23 04:05PM
Sep-19-23 04:32PM
Sep-05-23 04:05PM
Aug-30-23 08:00AM
Aug-17-23 04:00PM
Aug-11-23 07:00AM
Aug-08-23 12:38PM
Jul-20-23 08:00AM
Jun-29-23 04:49PM
Jun-22-23 04:00PM
08:00AM Loading…
Jun-02-23 08:00AM
May-09-23 10:43AM
08:00AM
08:00AM
May-07-23 08:17AM
Apr-25-23 08:00AM
Apr-24-23 08:00AM
Apr-18-23 08:00AM
Mar-28-23 08:00AM
Mar-06-23 08:00AM
Feb-27-23 08:00AM
Feb-15-23 05:40AM
Feb-14-23 10:15AM
Jan-22-23 03:31PM
Nov-14-22 10:16PM
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 11 '24Buy8.502,353,00020,000,5005,360,858Apr 15 08:53 AM
Chione Ltd10% OwnerJun 26 '23Sale12.93162073,848,632Jun 28 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16 '23Option Exercise3.639,50034,48529,530Jun 20 05:21 PM
Chione Ltd10% OwnerJun 15 '23Sale12.142,05624,9603,848,648Jun 20 05:15 PM
Chione Ltd10% OwnerJun 14 '23Sale12.1389310,8323,850,704Jun 14 06:33 PM
Chione Ltd10% OwnerJun 13 '23Sale12.303,00036,9003,851,597Jun 14 06:33 PM
Chione Ltd10% OwnerJun 12 '23Sale12.342,00024,6803,854,597Jun 14 06:33 PM
Devroe EricChief Operating OfficerJun 05 '23Option Exercise1.049,2259,59462,883Jun 06 04:15 PM
Blume-Jensen PeterPresident and CEOMay 31 '23Option Exercise3.8833,605130,3872,403,702Jun 01 08:40 PM